Tailored aliphatic polyesters for stent coatings

• US 9,067,002 B2
• Filed: 02/20/2014
• Issued: 06/30/2015
• Est. Priority Date: 07/14/2006
• Status: Expired due to Fees

• Current Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Abbott Cardiovascular Systems Incorporated (Abbott Laboratories Incorporated)
• Inventors: Trollsas, O. Mikael, Kleiner, Lothar W., Hossainy, Syed F. A.
• Primary Examiner(s): Sasan, Aradhana
• Application Number:
  US14/185,699
• Publication Number:
  US 20140186417A1
• Time in Patent Office: 495 Days
• Field of Search: 424/425, 424/423
• US Class Current: 1/1
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2400/18 Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
• CPC Class Codes: A61L 2420/08 Coatings comprising two or more layers
• CPC Class Codes: A61L 27/34 Macromolecular materials
• CPC Class Codes: A61L 31/10 Macromolecular materials
• CPC Class Codes: A61L 31/148 Materials at least partially resorbable by the body
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: C08L 67/04 Polyesters derived from hydroxycarboxylic acids, e.g. lactones C08L67/06 takes precedence

Abstract

An aliphatic polyester polymer for stent coating is described.

Claims

1. A coating on a medical device, comprising a phosphorylcholine (PC) functionalized aliphatic absorbable polymer;

wherein the aliphatic absorbable polymer comprises poly glycerol sebacate.

2. The coating of claim 1, wherein the PC functionalized aliphatic polymer forms a thin topcoat on top of a matrix layer comprising a polyester and a bioactive agent.

3. The coating of claim 1, wherein the PC functionalized aliphatic polymer forms a thin topcoat on top of a pure drug layer that is formed on a primer layer or a medical device surface.

4. The coating of claim 1, formed on a bare metal stent or an absorbable stent.

5. The coating of claim 1, further comprising a bioactive agent.

6. The coating of claim 5, wherein the bioactive agent is paclitaxel, docetaxel, estradiol, 17-beta-estradiol, a nitric oxide donor, a super oxide dismutase, a super oxide dismutase mimic, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, dexamethasone acetate, rapamycin, a rapamycin derivative, 40-O-(2-hydroxyl)ethyl-rapamycin (everolimus), 40-O-(3-hydroxyl)propyl-rapamycin, 40-O-[2-(2-hydroxyl)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ

-hiridun, clobetasol, mometasone, pimecrolimus, imatinib mesylate, midostaurin, or a prodrug of these, a co-drug of these, or a combination of these.

7. The coating of claim 1, wherein the medical device is a stent.

8. The coating of claim 1, wherein the medical device is a bioabsorbable stent.

9. The coating of claim 1, wherein the PC functionalized aliphatic absorbable polymer comprises at least one PC moiety within the backbone of the polymer or as a pendant group off the polymer backbone.

10. A method of treating or ameliorating a medical condition in a patient, comprising implanting in the patient a medical device comprising the coating according to claim 1.

11. A method of treating or ameliorating a medical condition in a patient, comprising implanting in the patient a medical device comprising the coating according to claim 6.

12. The coating of claim 5, wherein the bioactive agent is paclitaxel, docetaxel, estradiol, 17-beta-estradiol, a nitric oxide donor, a super oxide dismutase, 4-amino-2,2,6,6-tetramethylpiperidine-1-oxyl (4-amino-TEMPO), tacrolimus, dexamethasone, dexamethasone acetate, rapamycin, 40-O-(2-hydroxyl)ethyl-rapamycin (everolimus), 40-O-(3-hydroxy)-propyl-rapamycin, 40-O-[2-(2-hydroxyl)ethoxy]ethyl-rapamycin, 40-O-tetrazole-rapamycin, 40-epi-(N1-tetrazolyl)-rapamycin (ABT-578), γ

-hiridun, clobetasol, mometasone, pimecrolimus, imatinib mesylate, midostaurin, or a combination of these.

13. A method of treating or ameliorating a medical condition in a patient, comprising implanting in the patient a medical device comprising the coating according to claim 12.

14. A medical device comprising the coating according to claim 1.

15. A medical device comprising the coating according to claim 2.

16. A medical device comprising the coating according to claim 3.

17. A medical device comprising the coating according to claim 4.

18. A medical device comprising the coating according to claim 5.

19. A medical device comprising the coating according to claim 6.

20. A medical device comprising the coating according to claim 12.

21. The coating of claim 2, wherein the polyester of the matrix layer is the same polymer as the aliphatic polymer functionalized with PC of the topcoat.

22. The coating of claim 2, wherein the polyester of the matrix layer is a different polymer than the aliphatic polymer functionalized with PC of the topcoat.

23. The coating of claim 3, wherein the medical device is a metal stent, and the pure drug layer is formed on the surface of the stent.

24. The coating of claim 3, wherein the medical device is an absorbable stent, and the pure drug layer is formed on the surface of the stent.